Skip to content

PharmaLex Belgium

Active
Public limited companyfounded 2016active for 9 yearsWeiveldlaan 3, 1930 Zaventem, BelgiumKBO/BCE: BE 0667.829.063

From the official registers: KBO 8 annual accounts at the National Bank publications in the Belgian Official Gazette

Summary

The computed 12-month bankruptcy probability of PharmaLex Belgium is 6.7% (elevated). For PharmaLex Belgium, one annual filing is missing. The 2024 annual accounts show equity of €2.4m and a net result of -€102,323. Equity has been growing by about 43% per year since 2018. Its solvency ranks better than 49% of 4,582 sector peers (NACE 70, financial year 2024). The company has been active since 2016 and the Belgian Official Gazette contains no insolvency or warning signals.

Risk analysisFollow ReportCompare
PharmaLex BelgiumActive
Risk analysis ReportCompare

Overview

Official details

KBO
Status
Active since 19-12-2016 Normal situation
Activity
Business and other management consultancy NACE 70200and 1 other
Establishment unit
2.352.876.441 1930 Zaventem, since 01-08-2023
Financial year end
30 September
Peppol
Reachable since 10-12-2025
Company details

Board and ownership

Board
Auditor
Deloitte Réviseurs d'Entreprises
Shareholders
Board & ownership

Financial position

Bankruptcy probabilitywithin 12 months
6.7%
2024 figures too old to score
Annual accounts to 30-09-2024
Turnover
€8.4m
▲ 19.7%
Loss
€102,323
Equity
€2.4m
▼ 4.2%
Total assets
€5.0m
▼ 15.3%
Staff
47.1 FTE
▼ 5.8%
2025 accounts not filed, 185 days past the deadline
Filed on 19-08-2026at the National Bank
Financials
Signalsraises riskFigures for financial year 2024 (filed on 21-08-2026)2 changes of registered office in 24 months1 financial year not filed after the legal deadline; last filed accounts filed 476 days late; 2 of the last 3 accounts lateAnnual accounts not filed2024 accounts filed 476 days latelowers riskSector: Activities of head offices; management consultancy activities (NACE 70)Show the evidence

Bankruptcy probability

No current score
Figures too old
The latest figures are for FY 2024. They are too old for a current score.
Bankruptcy probability: Elevated
Filing: One annual filing is missing
Financial strength, FY 2024 · tick: 2023
Strong
Solvency 72+5
equity 47.4% of total assets
Liquidity 62-7
short-term debt 34.2% · cash 21.4%
Profitability 56-22
return on assets -2.1%
Bankruptcy probability within 12 months
6.7% Elevated
0%0.5%1.5%4%10%≥ 25%

About 7 in 100 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.1% (4,516 companies, NACE 70, small)
Last 24 months 12-2024: 0.1% 01-2025: 0.1%● unchanged vs 12-2024lowest value 02-2025: 0.1%● unchanged vs 01-2025 03-2025: 0.1%● unchanged vs 02-2025 04-2025: 0.1%● unchanged vs 03-2025 05-2025: 0.2%▲ +0.1 percentage points vs 04-2025 06-2025: 0.2%● unchanged vs 05-2025 07-2025: 0.4%▲ +0.2 percentage points vs 06-2025 08-2025: 0.4%● unchanged vs 07-2025 09-2025: 0.5%▲ +0.1 percentage points vs 08-2025 10-2025: 0.6%▲ +0.1 percentage points vs 09-2025 11-2025: 0.6%● unchanged vs 10-2025 12-2025: 0.6%● unchanged vs 11-2025 01-2026: 0.6%● unchanged vs 12-2025 02-2026: 0.6%● unchanged vs 01-2026 03-2026: 0.6%● unchanged vs 02-2026 04-2026: 0.6%● unchanged vs 03-2026 05-2026: 3.6%▲ +3.0 percentage points vs 04-2026 06-2026: 3.6%● unchanged vs 05-2026 07-2026: 3.6%● unchanged vs 06-2026 08-2026: 3.9%▲ +0.3 percentage points vs 07-2026 09-2026: 5.1%▲ +1.2 percentage points vs 08-2026 10-2026: 6.7%▲ +1.6 percentage points vs 09-2026highest value 11-2026: 6.7%● unchanged vs 10-2026highest value
Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Six signals.
lowers riskraises risk
raises risk · Figures for financial year 2024 (filed on 21-08-2026)
NBB · annual accounts
raises risk · 2 changes of registered office in 24 months
Belgian Official Gazette
raises risk · 1 financial year not filed after the legal deadline; last filed accounts filed 476 days late; 2 of the last 3 accounts late
NBB · filings
lowers risk · Sector: Activities of head offices; management consultancy activities (NACE 70)
KBO
raises risk · Annual accounts not filed
The financial year that closed on 30-09-2025 was due at the National Bank by 30-04-2026. Nothing is on record, 185 days later.
NBB · 8 filings
Position against the passed deadline
30-09-2025 year end30-04-2026 deadline01-11-2026 today
raises risk · 2024 accounts filed 476 days late
The financial year that closed on 30-09-2024 was due by 30-04-2025 and was filed on 19-08-2026, 476 days past the deadline. Measured on financial year 2023: of the companies more than 90 days late, 5.61% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers.
NBB · 8 filings
Deviation from the deadline
2025
not filed
2024
476 days late
2023
84 days late
2022
7 days early
2021
2 days early
2020
8 days early
2019
8 days early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

The company filed its last 6 accounts on average 89 days after the deadline. In the sector (NACE 70), the median for financial year 2024 was 9 days before the deadline, and 32% of those companies filed late.

Searched, nothing found (1)
neutral · No strike-offs in the KBO publications
That holds for every publication since 2021.
KBO publications

Key points

  • Caution: Board changedlatest change 01-10-2026 · 4 in office 4 joined · 4 left View
  • Caution: Lower net result than 90% of companies in head offices and management consultancysector median €45,241 · 4,593 companies -€102,323 View
  • Caution: From profit to loss in 2024after a profit of €577,668 in 2023 -€102,323 View
  • Positive: 6 years of growth in a rowturnover 2024: €8.4m 6 years View

Comparable companies

These companies have the same main activity as PharmaLex Belgium: business and other management consultancy (NACE 70200). They are comparable in size and age: total assets between €3.8m and €6.5m, founded between 2009 and 2019.

CompanyTotal assetsTurnover
PharmaLex Belgium Zaventem€5.0m€8.4m
KPMG Deal Advisory Zaventem€6.0m€11.1m
EY SOLUTIONS Machelen (Brab.)€5.4m€13.7m
RUD PEDERSEN PUBLIC AFFAIRS BRUSSELS Brussel€3.8m€11.6m
JLG Ground Support Europe Genk€6.5m€12.7m
EMAC Belgium Charleroi€5.6m€7.3m
Care 4 Fleets Vilvoorde€5.7m€14.9m
Full comparison

Documents

Annual accounts at the NBB

All 8 annual accounts

Acts in the Belgian Official Gazette

All publications in the Belgian Official Gazette

Articles and registers

Key facts about PharmaLex Belgium
What is the company number of PharmaLex Belgium?
The company number of PharmaLex Belgium is 0667.829.063. The VAT number is the same number with BE in front: BE 0667.829.063.
Where is PharmaLex Belgium based?
The registered office is at Weiveldlaan 3, 1930 Zaventem.Company details
What does PharmaLex Belgium do?
According to the KBO register, the main activity is business and other management consultancy (NACE 70200).
What is the legal form of PharmaLex Belgium?
The legal form of PharmaLex Belgium is Public limited company (NV).
When was PharmaLex Belgium founded?
PharmaLex Belgium was founded on 19-12-2016.
Is PharmaLex Belgium still active?
Yes, PharmaLex Belgium is an active enterprise in the KBO register.
How many employees does PharmaLex Belgium have?
PharmaLex Belgium had an average of 47.1 full-time equivalents in financial year 2024, according to the filed annual accounts.Financials
What is the turnover of PharmaLex Belgium?
The turnover of PharmaLex Belgium was €8.4m in financial year 2024, according to the filed annual accounts.
Is PharmaLex Belgium profitable?
In financial year 2024, PharmaLex Belgium made a loss of €102,323.
Where can I find the annual accounts of PharmaLex Belgium?
PharmaLex Belgium filed 8 annual accounts with the National Bank of Belgium, the latest for financial year 2024.Annual accounts at the National Bank

Next steps

Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See which support similar companies received that this one did not.Subsidies Compare this company with its sector.Sector benchmark

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.

We would like to set cookies. That happens only with your consent. What we measure